MicroCME: Currently Available Options for Treatment for Refractory Disease
Price: FREE to members; $20 non-members
Length: 23 minutes
This microlearning, presented by Dr. David Khan, discusses currently available options for treatment for refractory disease.
Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience
Practicing allergists
Allied health professionals
Primary Care Providers
Fellows-in-Training
Learning Objectives
By participating in this course, learners should be able to:
- Comprehend the international guidelines for the management of patients with CSU, revisit current treatment recommendations and understand the burden of refractory disease.
- Discuss therapeutics currently FDA-approved for other indications, now under investigation for treatment of CSU and ISM.
- Review recent data on novel therapeutics under investigation for CSU and ISM.
Mary Beth Hudelson, MD, FACAAI, planner/reviewer
Joel Klein, MD, FACAAI, planner
Tammy Peng, MD, planner
Desha Jordan, MD, planner
Karen Anstey, MD, planner
Evelyn Lomasney, MD, planner
Deepa Patadia, MD, planner
Brianne Nicole Navetta-Modrov, MD, planner
Farrah Khan, MD, planner
Available Credit
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Attendance